Merus N.V.

Merus N.V. is a clinical-stage immuno-oncology company based in Utrecht, the Netherlands. The company specializes in the discovery and development of bispecific antibody therapeutics. Merus has a pipeline of bispecific antibody candidates, including Zenocutuzumab (MCLA-128), MCLA-158, MCLA-145, MCLA-129, and ONO-4685.

Zenocutuzumab (MCLA-128) is the lead candidate in Merus’ pipeline and is currently in Phase 2 clinical trials for the treatment of metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. MCLA-158 is being evaluated in a Phase I clinical trial for the treatment of solid tumors, while MCLA-145 is in Phase 1 clinical trials for the same indication. MCLA-129 is in Phase 1/2 clinical trials for the treatment of advanced non-small cell lung cancer and other solid tumors. Lastly, ONO-4685 is in Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.

Merus has a number of partnerships and collaborations in place. The company has a collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates, including MCLA-129. Merus also has a collaboration with Incyte Corporation for the development of MCLA-145.

Merus was founded in 2003 and is now a publicly traded company on the Euronext Amsterdam Stock Exchange. Merus is focused on the development of novel therapies to improve patient outcomes in oncology and other therapeutic areas. The company is committed to delivering innovative, safe, and effective treatments to patients in need.